Effect of fluoxetine intervention on clinical efficacy and neurological function rehabilitation in patients with depression after cerebral infarction
10.3760/cma.j.issn.1008-6706.2019.18.006
- VernacularTitle: 氟西汀治疗脑梗死后抑郁症的临床疗效及对患者神经功能康复的影响
- Author:
Guomin WANG
1
;
Zhifang MAO
2
;
Lifeng ZHENG
1
;
Xiaocui ZHANG
1
;
Kairen YANG
3
Author Information
1. The Seventh Ward, the Third People's Hospital of Quzhou, Quzhou, Zhejiang 324000, China
2. Department of Neurology, the Third People's Hospital of Quzhou, Quzhou, Zhejiang 324000, China
3. Department of Clinical Psychology, the Third People's Hospital of Quzhou, Quzhou, Zhejiang 324000, China
- Publication Type:Journal Article
- Keywords:
Depression;
Brain infarction;
Fluoxetine;
Anxiety;
Quality of life
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(18):2200-2203
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical effect of fluoxetine in the treatment of patients with post-cerebral infarction depression (PSD) and its influence on neurological rehabilitation.
Methods:From February 2017 to February 2018, 92 PSD patients received treatment in the department of neurology of the Third People's Hospital of Quzhou were included in the study.The patients were randomly divided into two groups according to the digital table, with 46 cases in each group.The control group was treated with specialist symptomatic therapy, while the study group was treated with fluoxetine intervention for 4 weeks.The Hamilton anxiety scale (HAMD), neurological deficit scale (NIHSS) and daily living capacity scale (ADL) were used to evaluate the clinical effects of the two groups, and the adverse reactions of the two groups were observed.
Results:One week before treatment, the HAMD, NIHSS and ADL scores of the study group were (28.37±2.18)points, (23.10±3.16)points and (40.61±3.52)points, respectively, which of the control group were (28.30±2.24)points, (22.91±3.20)points and (41.15±3.35)points, respectively, there were no statistically significant differences between the two groups (t=0.223, 1.522, 0.761, all P>0.05). After 2 weeks of treatment, the HAMD, NIHSS and ADL scores of the study group were (21.08±2.33)points, (19.27±2.89)points and (49.26±2.88)points, respectively, which were higher than those of the control group[(24.15±2.43)points, (21.16±2.18)points, (44.26±2.54)points](t=4.384, 10.216, 8.276, all P<0.05). After 4 weeks of treatment, the HAMD, NIHSS and ADL scores of the study group were (12.61±1.87)points, (10.12±1.30)points, (70.13±2.16)points, respectively, which were higher than those of the control group[(15.20±2.06)points, (17.45±2.66)points, (51.19±2.46)points](t=7.273, 18.283, 5.371, all P<0.05). The total effective rate of neurological recovery in the study group was 91.30%(42/46), the total effective rate of depression treatment was 84.78%(39/46), which in the control group were 76.09%(35/46) and 65.22%(30/46), respectively, the differences were statistically significant (χ2=3.903, 4.696, all P<0.05).
Conclusion:The application of fluoxetine in the treatment of PSD can effectively improve the patients' depressive symptoms, promote the recovery of neurological function, improve self-care ability, and has high safety.It has important clinical value.
